Cargando…

Pretreatment albumin is a prognostic and predictive biomarker for response to atezolizumab across solid tumors

OBJECTIVES: Reliable predictive biomarkers for response to immune checkpoint inhibition (ICI) are lacking. Pretreatment serum albumin, a known prognostic and predictive factor in ICI‐treated patients, has been proposed as a potential pharmacokinetic surrogate marker for anti‐PD1/PD‐L1 antibodies, as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saal, Jonas, Ellinger, Jörg, Ritter, Manuel, Brossart, Peter, Hölzel, Michael, Klümper, Niklas, Bald, Tobias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632074/ https://www.ncbi.nlm.nih.gov/pubmed/37946873 http://dx.doi.org/10.1002/cti2.1472

Ejemplares similares

Early C-reactive protein kinetics predicts immunotherapy response in non-small cell lung cancer in the phase III OAK trial
por: Saal, Jonas, et al.
Publicado: (2023)

Integrating On-Treatment Modified Glasgow Prognostic Score and Imaging to Predict Response and Outcomes in Metastatic Renal Cell Carcinoma
por: Saal, Jonas, et al.
Publicado: (2023)

C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer
por: Klümper, Niklas, et al.
Publicado: (2022)

Downstream neighbor of SON (DONSON) is associated with unfavorable survival across diverse cancers with oncogenic properties in clear cell renal cell carcinoma
por: Klümper, Niklas, et al.
Publicado: (2020)

CircEHD2, CircNETO2 and CircEGLN3 as Diagnostic and Prognostic Biomarkers for Patients with Renal Cell Carcinoma
por: Frey, Lisa, et al.
Publicado: (2021)

Insights into Urologic Cancer
por: Klümper, Niklas, et al.
Publicado: (2023)

Identification of F-Box/SPRY Domain-Containing Protein 1 (FBXO45) as a Prognostic Biomarker for TMPRSS2–ERG-Positive Primary Prostate Cancers
por: von Danwitz, Marthe, et al.
Publicado: (2023)

CDCP1 expression is frequently increased in aggressive urothelial carcinoma and promotes urothelial tumor progression
por: Saponaro, Miriam, et al.
Publicado: (2023)

Author Correction: CDCP1 expression is frequently increased in aggressive urothelial carcinoma and promotes urothelial tumor progression
por: Saponaro, Miriam, et al.
Publicado: (2023)

Downstream Neighbor of SON (DONSON) Expression Is Enhanced in Phenotypically Aggressive Prostate Cancers
por: Klümper, Niklas, et al.
Publicado: (2020)

LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma
por: Klümper, Niklas, et al.
Publicado: (2020)

CD103+ Tissue Resident T-Lymphocytes Accumulate in Lung Metastases and Are Correlated with Poor Prognosis in ccRCC
por: Sanders, Christine, et al.
Publicado: (2022)

Prognostic Role of the Pretreatment C-Reactive Protein/Albumin Ratio in Solid Cancers: A Meta-Analysis
por: Li, Nan, et al.
Publicado: (2017)

CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma
por: Klümper, Niklas, et al.
Publicado: (2021)

Fibrinogen–Albumin Ratio Index (FARI) as a Certain Prognostic Biomarker in Pretreated Patients with Immunotherapy
por: Guo, Ziwei, et al.
Publicado: (2021)

Identification of the dopamine transporter SLC6A3 as a biomarker for patients with renal cell carcinoma
por: Schrödter, Sarah, et al.
Publicado: (2016)

Cultivation of Clear Cell Renal Cell Carcinoma Patient-Derived Organoids in an Air-Liquid Interface System as a Tool for Studying Individualized Therapy
por: Esser, Laura K., et al.
Publicado: (2020)

Systematic expression analysis of m(6)A RNA methyltransferases in clear cell renal cell carcinoma
por: Gundert, Larissa, et al.
Publicado: (2021)

The Glasgow Prognostic Score Predicts Outcomes of Pembrolizumab or Atezolizumab Monotherapy in Patients with Pretreated Non-Small Cell Lung Cancer
por: Kasajima, Masashi, et al.
Publicado: (2023)

A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis
por: Ikeda, Satoshi, et al.
Publicado: (2020)

Prognostic significance of pretreatment albumin/globulin ratio in patients with hepatocellular carcinoma
por: Deng, Yan, et al.
Publicado: (2016)

N6-methyladenosine RNA modification (m6A) is of prognostic value in HPV-dependent vulvar squamous cell carcinoma
por: Condic, Mateja, et al.
Publicado: (2022)

Pretreatment Modified Albumin–Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma
por: Tanaka, Takashi, et al.
Publicado: (2022)

Atezolizumab in Patients with Pretreated Urothelial Cancer: a Korean Single-Center, Retrospective Study
por: Hur, Joon Young, et al.
Publicado: (2019)

Pretreatment values of bilirubin and albumin are not prognostic predictors in patients with advanced pancreatic cancer
por: Feng, Lanyun, et al.
Publicado: (2018)

Prognostic significance of pretreatment serum lactate dehydrogenase-to-albumin ratio in gastric cancer
por: Aday, Ulaş, et al.
Publicado: (2020)

Two cases of EBV infection preceding lymphoma
por: Saal, Jonas, et al.
Publicado: (2022)

C‐reactive protein flare‐response predicts long‐term efficacy to first‐line anti‐PD‐1‐based combination therapy in metastatic renal cell carcinoma
por: Klümper, Niklas, et al.
Publicado: (2021)

Pretreatment serum albumin/globulin ratio as a prognostic biomarker in metastatic prostate cancer patients treated with maximal androgen blockade
por: Wang, Ning, et al.
Publicado: (2019)

Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma
por: Maesaka, Kazuki, et al.
Publicado: (2023)

PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma
por: Klümper, Niklas, et al.
Publicado: (2023)

Prognostic impact of the pretreatment albumin to alkaline phosphatase ratio for nonmetastatic breast cancer patients
por: Long, Zhi-Qing, et al.
Publicado: (2019)

Prognostic Value of Pretreatment Albumin-to-Alkaline Phosphatase Ratio in Cancer: A Meta-Analysis
por: Xie, Hailun, et al.
Publicado: (2020)

Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma
por: Eso, Yuji, et al.
Publicado: (2021)

Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer
por: Wasamoto, Satoshi, et al.
Publicado: (2023)

Prognostic value of pretreatment albumin/globulin ratio in digestive system cancers: A meta-analysis
por: Guo, Hui-Wen, et al.
Publicado: (2018)

Prognostic value of pretreatment albumin to bilirubin ratio in patients with hepatocellular cancer: A meta-analysis
por: Xu, Yi-Xin, et al.
Publicado: (2019)

Clinical and prognostic implications of pretreatment albumin to C-reactive protein ratio in patients with hepatocellular carcinoma
por: Wu, Mian-Tao, et al.
Publicado: (2019)

Prognostic effect of pretreatment albumin-to-alkaline phosphatase ratio in human cancers: A meta-analysis
por: Guo, Xiaoli, et al.
Publicado: (2020)

Cystoid Macular Edema following Treatment with Nanoparticle Albumin-Bound Paclitaxel and Atezolizumab for Metastatic Breast Cancer
por: Yamane, Hiroaki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fi7i5sjouljnrg1jo3lnho7bls